Antibe’s recent Phase 2B GI safety study provides unequivocal evidence for a marked reduction of GI toxicity of its H2S‐releasing analgesic/anti‐inflammatory drug, ATB‐346, as compared to the conventional dose of naproxen that produced equivalent suppression of cyclooxygenase (COX). This peer-reviewed paper was published in one of the world’s leading pharmacology journals and provides a comprehensive summary of the clinical trial results.
